Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Oralin set to enter phase IIb shortly

June 5, 2003

Nicotine increases muscle girth, decreases body weight and reduces appetite in mice

June 5, 2003

Wyeth presents new estrogenic agents with utility in osteoporosis, cancer, IBD, etc.

June 5, 2003

Amine salts of alphavbeta3 integrin antagonist covered by Merck patent

June 5, 2003

FDA sets Hemopure review date

June 4, 2003

New series of GSK-3beta inhibitors under study at Janssen

June 4, 2003

New glucose-lowering agents covered by BMS patent

June 3, 2003

Enrollment under way in pivotal Pompe's disease study of Myozyme

June 2, 2003

Merck discontinues development of two diabetes projects

June 2, 2003

Novel antiobesity agents in Bayer development pipeline

June 2, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Case report links APOLD1 variant to vascular-type bleeding disorder
BioWorld Science
Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...